Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover secondary buyers as an exit strategy for Boston Scientific and others; a review of medtech dealmaking in the first quarter of 2008, and US markets for patient monitoring products.
You may also be interested in...
As critical care migrates from intensive care units to other areas of the hospital, hemodynamic monitors--essential for patient diagnosis and prognosis--must make the move as well. At this year's annual meeting of the Society of Critical Care Medicine, clinicians and researchers discussed the need and the market challenges for hemodynamic monitoring technologies that are simpler to use, less invasive and allow for earlier diagnosis of sepsis and shock.
Over the last three years, deal values in medical device M&A have hit all time highs, with more big deals done than ever before. Still, even with deal values soaring, device M&A remains a small-stakes game. IN VIVO looks at dealmaking in medtech by therapeutic and industry segments.
Boston Scientific agreed to divest itself of its TriVascular abdominal aortic aneurysm company, selling it for $65 million to MPM Capital, New Enterprise Associates, Kearny Venture Partners and Delphi Ventures.